US 11,986,477 B2
Drug combination and use for treating tumors
Baoyuan Zhang, Shanghai (CN); Xuebin Liu, Nanjing (CN); Jiaming Gao, Shanghai (CN); Ping Zhang, Nanjing (CN); Ran Pang, Nanjing (CN); and Zaiqi Wang, Shanghai (CN)
Assigned to INXMED (NANJING) CO., LTD., Nanjing (CN)
Filed by INXMED (NANJING) CO., LTD., Nanjing (CN)
Filed on Nov. 6, 2023, as Appl. No. 18/387,180.
Application 18/387,180 is a continuation of application No. PCT/CN2023/101720, filed on Jun. 21, 2023.
Claims priority of application No. 202210730136.2 (CN), filed on Jun. 24, 2022.
Prior Publication US 2024/0082247 A1, Mar. 14, 2024
Int. Cl. A61K 31/506 (2006.01); A61P 35/00 (2006.01)
CPC A61K 31/506 (2013.01) [A61P 35/00 (2018.01)] 15 Claims
 
1. A method of treating a tumor, which comprises administering to a subject in need thereof a therapeutically effective amount of IN10018 or a pharmaceutically acceptable salt thereof and an epidermal growth factor receptor tyrosine kinase inhibitor, wherein the IN10018 has a structure of:

OG Complex Work Unit Chemistry
and
the epidermal growth factor receptor tyrosine kinase inhibitor is selected from the group consisting of Icotinib, Afatinib, Crizotinib, Osimertinib (AZD9291), Almonertinib, Alflutinib (also known as Furmonertinib), EAI045, JBJ-25-02, BLU945, BLU701, TOB3804, BBT-176, ES-072, BPI-361175, CH7233163, and a pharmaceutically acceptable salt thereof.